Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБОУ ВО «Санкт-Петербургский государственный университет». 199034, Россия, Санкт-Петербург, Университетская наб., д. 7/9
Список исп. литературыСкрыть список 1. Гурович И.Я., Шмуклер А.Б., Сторожакова Я.А. Ремиссии и личностно-социальное восстановление (recovery) при шизофрении: предложения к 11 пересмотру МКБ. Соц. и клин. психиатрия. 2008; 18 (4): 34–9. / Gurovich I.Ia., Shmukler A.B., Storozhakova Ia.A. Remissii i lichnostno-sotsial'noe vosstanovlenie (recovery) pri shizofrenii: predlozheniia k 11 peresmotru MKB. Sots. i klin. psikhiatriia. 2008; 18 (4): 34–9. [in Russian] 2. Краснов В.Н., Гурович И.Я., Мосолов С.Н. и др. Стандарты оказания помощи больным шизофренией. М., 2006. / Krasnov V.N., Gurovich I.Ia., Mosolov S.N. i dr. Standarty okazaniia pomoshchi bol'nym shizofreniei. M., 2006. [in Russian] 3. Гурович И.Я., Шмуклер А.Б., Сторожакова Я.А. Психосоциальная терапия и психосоциальная реабилитация в психиатрии. М.: Медпрактика, 2004. / Gurovich I.Ya., Shmukler A.B., Storozhakova Ia.A. Psikhosotsial'naia terapiia i psikhosotsial'naia reabilitatsiia v psikhiatrii. M.: Medpraktika, 2004. [in Russian] 4. Andreasen NC, Carpenter WT, Kane JM et al. Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus. Am J Psychiatry 2005; 162: 441–9. 5. Мосолов С.Н., Потапов А.В., Ушаков Ю.В. и др. Стандартизированные клинико-функциональные критерии терапевтической ремиссии при шизофрении: разработка и валидизация. Психиатрия и психофармакотерапия. 2012; 14 (2): 9–19. / Mosolov S.N., Potapov A.V., Ushakov Yu.V. et al. Standartizirovannye kliniko-funktsional'nye kriterii terapevticheskoi remissii pri shizofrenii: razrabotka i validizatsiia. Psychiatry and Psychopharmacotherapy. 2012; 14 (2): 9–19. [in Russian] 6. Мосолов С.Н., Потапов А.В., Шафаренко А.А. и др. Разработка и валидизация стандартизированных критериев терапевтической ремиссии при шизофрении. Соврем. терапия психических расстройств. 2011; (3): 2–6. / Mosolov S.N., Potapov A.V., Shafarenko A.A. i dr. Razrabotka i validizatsiia standartizirovannykh kriteriev terapevticheskoi remissii pri shizofrenii. Sovrem. terapiia psikhicheskikh rasstroistv. 2011; (3): 2–6. [in Russian] 7. Чуркин А.А., Казаковцев Б.А., Творогова Н.А. и др. Распространенность психических расстройств в населении Российской Федерации в 2011 году. Аналитический обзор. М.: ФМИЦПН, 2014. / Churkin A.A., Kazakovtsev B.A., Tvorogova N.A. i dr. Rasprostranennost' psikhicheskikh rasstroistv v naselenii Rossiiskoi Federatsii v 2011 godu. Analiticheskii obzor. M.: FMITsPN, 2014. [in Russian] 8. Петрова Н.Н., Гвоздецкий А.Н., Вишневская О.А. Социальное функционирование больных параноидной шизофренией в ремиссии. Соц. и клин. психиатрия. 2012; 22 (4): 31–5. / Petrova N.N., Gvozdetskii A.N., Vishnevskaia O.A. Sotsial'noe funktsionirovanie bol'nykh paranoidnoi shizofreniei v remissii. Sots. i klin. psikhiatriia. 2012; 22 (4): 31–5. [in Russian] 9. Lecrubier Y, Azorin M, Bottai T et al. Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia. Neuropsychobiology 2001; 44 (1): 41–6. 10. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353 (12): 1209–23. 11. Руководство по биологической терапии Всемирной федерации обществ биологической терапии (WFSBP). Обновленная ред. 2012 г. Соврем. терапия психических расстройств. 2013; 1: 3–40. / Rukovodstvo po biologicheskoi terapii Vsemirnoi federatsii obshchestv biologicheskoi terapii (WFSBP). Obnovlennaia red. 2012 g. Sovrem. terapiia psikhicheskikh rasstroistv. 2013; 1: 3–40. [in Russian] 12. Alkelai A, Greenbaum L, Lupoli S et al. Association of the Type 2 Diabetes Mellitus Susceptibility Gene, TCF7L2, with Schizophrenia in an Arab-Israeli Family Sample. PLoS ONE 2012; 7 (1): e29228. https://doi.org/10.1371/journal.pone.0029228 13. Ferentinos P, Dikeos D. Genetic correlates of medical comorbidity associated with schizophrenia and treatment with antipsychotics. Curr Opin Psychiatry 2012; 25: 381–90. 14. Saravane D, Feve B, Frances Y et al. Drawing up guidelines for the attendance of physical health of patients with severe mental illness. Encephale 2009; 35 (4): 330–9. 15. Bobes J, Rejas J, García-García M et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the Eire Study. Schizophr Res 2003; 62: 77–88. 16. Аведисова А.С., Ахапкин Р.В. Проблемы клинической оценки переносимости терапии психотропными препаратами. Психиатрия и психофармакотерапия. 2005; 7 (1): 9–12. / Avedisova A.S., Akhapkin R.V. Problemy klinicheskoi otsenki perenosimosti terapii psikhotropnymi preparatami. Psychiatry and Psychopharmacotherapy. 2005; 7 (1): 9–12. [in Russian] 17. Мосолов С.Н. Современный этап развития психофармакотерапии. РМЖ. 2002; 12: 560. / Mosolov S.N. Sovremennyi etap razvitiia psikhofarmakoterapii. RMZh. 2002; 12: 560. [in Russian] 18. Stahl S.M. Основные направления и невостребованные аспекты в изучении шизофрении. В кн.: Дофаминовая теория патогенеза шизофрении. Руководство для врачей. Под ред. С.Н.Мосолова. London, New York: Taylor & Francis. 2004; с. 147–53. / Stahl S.M. Osnovnye napravleniia i nevostrebovannye aspekty v izuchenii shizofrenii. V kn.: Dofaminovaia teoriia patogeneza shizofrenii. Rukovodstvo dlia vrachei. Pod red. S.N.Mosolova. London, New York: Taylor & Francis. 2004; s. 147–53. [in Russian] 19. Leucht S, Corves C, Arbter D et al. Second-generation versus first generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31–41. 20. Tandon R, Nasrallah H, Keshavan MS. Schizophrenia. "Just the facts" 5. Treatment and prevention. Past, present and future. Schizophr Res 2010; 122: 1–23. 21. Kasper S. Clinical decisions (algorithms) in the pharmacotherapy of schizophrenia. Japanese J Neurospychopharmacol 2000; 20: 273. 22. Тэндон Р., Джибсон M.Д. Сравнение эффективности атипичных антипсихотиков первой линии: отсутствие значимых различий в эффективности рисперидона, оланзапина, кветиапина, ципразидона, арипипразола. РМЖ. 2007; 24: 1855. / Tendon R., Dzhibson M.D. Sravnenie effektivnosti atipichnykh antipsikhotikov pervoi linii: otsutstvie znachimykh razlichii v effektivnosti risperidona, olanzapina, kvetiapina, tsiprazidona, aripiprazola. RMZh. 2007; 24: 1855. [in Russian] 23. Lindstrom E, Farde L, Eberhard J et al. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole. Int J Neuropsychopharmacol 2005; 8: 615–29. 24. Woo YS, Kim W, Chae JH et al. Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients. World J Biol Psychiatry 2008; 6: 1–6. 25. Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382 (9896): 940. 26. Komossa K, Rummel-Kluge C, Schmid F et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2014; 4: CD006569. 27. Данилов Д.С., Магомедова Д.О. Опыт перевода с клозапина на арипипразол больных приступообразными формами шизофрении в период лекарственной ремиссии. Психиатрия и психофармакотерапия. 2013; 15 (6): 23–9. / Danilov D.S., Magomedova D.O. Transition experience from clozapine to aripiprazole with patients having intermittent schizophrenia within the period of therapeutic remission. Psychiatry and Psychopharmacotherapy. 2013; 15 (6): 23–9. [in Russian] 28. Kim SW et al. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol 2009; 32 (5): 243–9. 29. Travis M, Burns T, Dursun S et al. Арипипразол при шизофрении: согласованное руководство (расширенный реферат). Психиатрия и психофармакотерапия. 2006; 8 (5): 79–87. / Travis M, Burns T, Dursun S et al. Aripiprazol pri shizofrenii: soglasovannoe rukovodstvo (rasshirennyi referat). Psychiatry and Psychopharmacotherapy. 2006; 8 (5): 79–87. [in Russian] 30. Masand PS, Berry SL. Switching antipsychotic therapies. Ann Pharmacother 2000; 34: 200–7. 31. Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry 2007; 68 (Suppl. 6): 10–3. 32. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry 2008; 69 (Suppl. 1): 4–17. 33. Lin CH, Kuo CC, Chou LS et al. A randomized, double-blind compa-rison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia. J Clin Psychopharmacol 2010; 30: 518–25. 34. Reinstein MJ, Sirotovskaya LA, Jones LE et al. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control: preliminary findings. Clin Drug Invest 1999; 18: 99–104. 35. Ziegenbein M, Kropp S, Kuenzel HE. Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. Clin Neuropharmacol 2005; 28: 220–4. 36. Rocha FL, Hara C. Benefits of combining aripiprazole to clozapine: three case reports. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1167–9. 37. Fleischhacker WW, Heikkinen ME, Olie JP et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010; 13: 1115–25. 38. Henderson DC, Fan X, Copeland PM et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 2009; 29: 165–9. 39. Karunakaran K, Tungaraza TE, Harborne GC. Is clozapine-ari-piprazole combination a useful regime in the management of treatment-resistant schizophrenia? J Psychopharmacol 2007; 21: 453–6. 40. Henderson DC, Kunkel L, Nguyen DD et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006; 113: 142–7. 41. Chang JS, Ahn YM, Park HJ et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008; 69: 720–31. 42. Chen CK, Huang YS, Ree SC et al. Differential add-on effects of ari-piprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1495–9. 43. Kuwilsky A, Krumm B, Englisch S et al. Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone. Pharmacopsychiatry 2010; 43: 216–20. 44. Mir A, Shivakumar K, Williamson RJ et al. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol 2008; 22: 244–53. 45. Shim JC, Shin JG, Kelly DL et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007; 164: 1404–10. 46. Shores LE. Normalization of risperidone-induced hyperprolactinemia with the addition of aripiprazole. Psychiatry (Edgmont) 2005; 2: 42–5. 47. Yasui-Furukori N, Furukori H, Sugawara N et al. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol 2010; 30: 596–9. 48. Zink M, Kuwilsky A, Krumm B et al. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. J Psychopharmacol 2009; 23: 305–14. 49. Gardner DM, Teeha MD. Antipsychotics and their side effects. Cambridge University Press, 2011. 50. Qiao Y, Yang F, Li C et al. Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone. Psychiatry Res 2016; 237: 83–9. 51. Kane JM, Correll CU, Goff DC et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive ari-piprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 2009; 70 (10): 1348–57. 52. Choi Y-J. Efficacy of Adjunctive Treatments Added to Olanzapine or Clozapine for Weight Control in Patients with Schizophrenia: A Systematic Review and Meta-Analysis. Sci World J 2015; 2015: ID 970730. 53. Fan X, Borba CP, Copeland P et al. Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand 2013; 127: 217–26. 54. Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human D2 dopamine receptors. J Pharmacol Exp Ther 2002; 302: 381–9. 55. Correll CU, Rummel-Kluge C, Corves C et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009; 35 (2): 443–57. 56. Jordan S, Koprivica V, Chen R et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002; 441: 137–40. 57. McQuade R, Burris KD, Jordan S et al. Aripiprazole: a dopamine-serotonin system stabilizer. Int J Neuropsychopharmacol 2002; 5 (Suppl. 1): S176. 58. Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors. J Pharmacol Exp Ther 2000; 295: 853–61. 59. Carlsson A, Waters N, Waters S, Carlsson ML. Network interactions in schizophrenia – therapeutic implications. Br Res Rev 2000; 31: 342–9. 60. Carson WH, Stock E, Saha AR et al. Meta-analysis of efficacy with aripiprazole. Schizophr Res 2002; 53 (Suppl. 3): 1–274, Abstract B96. 61. Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763–71. 62. Marder SR, McQuade RD, Stock E et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term placebo-controlled trials. Schizophr Res 2003; 61: 123–36. 63. Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681–90. 64. Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat 2006; 2 (4): 427–43. 65. Stip E, Tourjman V. Аripiprazole in schizophrenia disorder. Clin Ther 2010; 32 (Suppl. A): 3–20. 66. Kane JM, Osuntokun O, Kryzhanovskaya LA et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry 2009; 70: 572–81. 67. McGavin K, Goa KL. Aripiprazole. CNS Drugs 2002; 16 (11): 779–86. 68. El-Sayeh HGG, Morganti C. Aripiprazole for schizophrenia (Review). The Cochrane Collaboration, 2006, Issue 2. Art. No.: CD004578. 69. Rocca P, Montemagni C, Castagna F et al. Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 373–9. 70. Riedel M et al. Effect of aripiprazole on cognition in the treatment of patients with schizophrenia. Pharmacopsychiatry 2010; 43: 50–7. 71. Kasper S, Lerman MN, McQuade RD et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003; 6: 325–37. 72. Koprivšek J, Vrzel M, Barbič-Žagar B. Učinkovitost in varnost ari-piprazola v zdravljenju shizofrenije in bipolarne manije. Efficacy and safety of aripiprazole in patients with schizophrenia and bipolar mania. VICEVERSA – glasilo Združenja psihiatrov pri Slovenskem zdravniškem društvu 2017; 62: 52–9.